Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.7 million versus the consensus estimate of $28.87 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Raymond James slaps Street-high $800 target on SpaceX, implying 440% upside
• H.C. Wainwright Reiterates Buy Rating on Terra Innovatum Global (NKLR)